Triple Antithrombotic Therapy for the Prevention of Left Ventricular Thrombus Following Anterior ST-Elevation

Anastasios Apostolos1,2, Vasileios Panoulas1,2

  • 1Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.

Insights

Triple antithrombotic treatment (TAT) does not reduce left ventricular thrombus (LVT) formation in anterior ST-elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (pPCI). TAT significantly increases major bleeding risk, questioning its routine prophylactic use.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Thrombosis Research

Background:

  • Left ventricular thrombus (LVT) is a significant complication following anterior ST-elevation myocardial infarction (STEMI).
  • Prophylactic anticoagulation is recommended for high-risk patients, but evidence quality is low.
  • Primary percutaneous coronary intervention (pPCI) is the standard reperfusion therapy for STEMI.

Purpose of the Study:

  • To evaluate the efficacy and safety of triple antithrombotic treatment (TAT) compared to dual antiplatelet therapy (DAPT) alone for LVT prevention.
  • To assess the impact of TAT on LVT formation, major bleeding, and systemic embolism in anterior STEMI patients undergoing pPCI.

Main Methods:

  • Systematic review and meta-analysis of six studies involving 2,021 patients.
  • Searched EMBASE, MEDLINE, and Cochrane Library databases following PRISMA 2020 guidelines.
  • Pooled data using random-effects models to calculate risk ratios (RR) and 95% confidence intervals (CI).

Main Results:

  • Triple antithrombotic treatment (TAT) did not significantly reduce left ventricular thrombus (LVT) formation (RR 0.54, p=0.21).
  • TAT significantly increased the risk of major bleeding (RR 2.69, p=0.003).
  • A non-significant trend towards reduced systemic embolism was observed with TAT (RR 0.44, p=0.07).

Conclusions:

  • Prophylactic TAT in anterior STEMI patients treated with pPCI does not significantly decrease LVT formation.
  • The increased risk of major bleeding associated with TAT outweighs potential benefits in unselected patients.
  • Routine prophylactic TAT is not supported for unselected anterior STEMI patients undergoing pPCI.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...